Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Severe asthma in pregnancy has historically been managed with structured corticosteroid use and reluctance to continue biologic therapy due to limited pregnancy-specific data. Real-world evidence on omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab continuation in pregnancy is accumulating, structured high-risk pregnancy pulmonology integration is formalising, and updated guidelines support continuation of biologic therapy in well-controlled pregnant patients. The maternal-fetal medicine and pulmonology integration is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is obstructive sleep apnea?